Table 2.

Myo-inositol: in vivo studies.

Author	Study Design and Patients	Treatments	Results
Calogero et al., 2015	Double-blind, randomized, place-bo-controlled; 194 men with idiopathic infertility	Group 1 (n = 98) received 2 g of myo-inositol and 200 mcg of folic acid twice daily. Group 2 (n = 96) received one placebo sachet twice day for 3 months	MI significantly increased the percentage of acrosome-reacted spermatozoa, sperm concentration, and total count and progressive motility. In addition, reduced serum luteinizing hormone, follicle-stimulating hormone, and in-creased inhibin B concentration
Gulino et al., 2013	Prospective study; 62 patients divided into three different groups: healthy fertile patients (Group A); patients with oligoasthenospermia (OA)–(Group B)–control group (CTR).	4000 mg/die of MI and 400 µg of folic acid for 2 months	Increase of basal and after density-gradient separation method spermatozoa concentration in Group B, and a significant increase of spermatozoa count after density-gradient separation method in Group A
Montanino Oliva et al., 2016	Prospective longitudinal study; 45 asthenospermic males	The patients were treated by a dietary supplement administered twice a day containing 1 g MI, 30 mg L-carnitine, L-arginine and vit-amin E, 55 μg selenium, and 200 μg folic acid	Improved spermatic, hormonal and metabolic parameters: HOMA index, SHBG, E2, LH, free and total testosterone, sperm concentration, motility and normal morphology
Dinkova et al. et al., 2017	Prospective longitudinal study; 109 patients with astheno-zoospermia	1 g myo-inositol, 30 mg of L-carnitine, L-arginine, and vitamin E, 55 mcg of selenium, and 200 mcg of folic acid twice a day for 3 months	A significant improvement in spermmotility was reported in 85.32% of the patients